FDMT 4D Molecular Therapeutics Inc
4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology. It develops genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution. It combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences. Its product design, development and manufacturing engine create a valuable and diverse product pipeline. The company is currently advancing five clinical-stage and two preclinical product candidates, each tailored to address rare and large market diseases. 4DMT was founded by David H. Kirn, Melissa Kotterman, Theresa Janke, and David Schaffer on September 12, 2013 and is headquartered in Emeryville, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
227
Frequently Asked Questions
What is Market Cap of 4D Molecular Therapeutics Inc?
What is the 52-week high for 4D Molecular Therapeutics Inc?
What is the 52-week low for 4D Molecular Therapeutics Inc?
What is 4D Molecular Therapeutics Inc stock price today?
What was 4D Molecular Therapeutics Inc stock price yesterday?
What is the PE ratio of 4D Molecular Therapeutics Inc?
What is the Price-to-Book ratio of 4D Molecular Therapeutics Inc?
What is the 50-day moving average of 4D Molecular Therapeutics Inc?
How many employess does 4D Molecular Therapeutics Inc has?